Most of those two weeks is not science. It is finding and assembling the data, which is also where most of the AI sold to pharma quietly stalls.
Investigación e Informes30 ago 2026•1 min de lectura
AI in Pharma Faces Data‑Gathering Delays, Not Scientific Limits
A recent note says most of the two‑week deviation investigation time is spent on data collection, not science, highlighting a bottleneck for AI tools in pharma.
Recopilado por el equipo de PharmaCountry · Fuente: FiercePharma
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración